Post Conference Perspectives: Immunotherapy Combinations for Unresectable HCC

Post Conference Perspectives: Immunotherapy Combinations for Unresectable HCC

Episodes

Specialty:

All

Year:

All

EP. 1: The Impact of Liver Pathobiology on HCC Treatment Approach

January 31st 2020

EP. 2: IMbrave150 Phase III Design, Results, and Practical Implications

January 31st 2020

EP. 3: The COSMIC-312 Phase III and Other Notable Trials

January 31st 2020

EP. 4: Challenges With Novel Treatment Strategies

January 31st 2020

EP. 5: Immunotherapy in Unresectable HCC

January 31st 2020

EP. 6: IMbrave150 in Unresectable HCC

January 31st 2020

EP. 7: Emerging I-O Combination Trials in Unresectable HCC

January 31st 2020

EP. 8: Sequencing With I-O Combinations in Unresectable HCC

January 31st 2020

EP. 9: Treating Unresectable HCC in the Community

January 31st 2020

EP. 10: Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

January 31st 2020

EP. 11: FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

January 31st 2020

Trending on OncLive

INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

The OncFive: Top Oncology Articles for the Week of 9/27/2026

NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC

Five Under 5: Top Oncology Videos for the Week of 9/27